Patents Assigned to THERALASE TECHNOLOGIES, INC.
  • Patent number: 11813330
    Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a sonosensitizing compound containing at least one transition metal with three bidentate ligands; and (b) exposing the sonosensitizing compound in the organism to ultrasound, wherein the ultrasound is effective to activate the sonosensitizing compound to destroy at least one of the cells and the microorganisms in the organism. The ultrasound is preferably used in conjunction with electromagnetic therapies comprising photodynamic therapy, low-level laser therapy, and radiation therapy. The ultrasound is preferably administered at a duty cycle in the range from 5% to 95% at a power density of 10 W/cm2 and a frequency in the range from 10 Hz to 10 MHz.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 14, 2023
    Assignee: THERALASE TECHNOLOGIES, INC.
    Inventors: Arkady Mandel, Roger Dumoulin-White
  • Patent number: 11793818
    Abstract: Disclosed is a method for treating a condition associated with hyperproliferating cells, the method including the steps of administering to a subject having the condition a composition including at least one cannabinoid receptor agonist, optionally administering to the subject a photodynamic compound, and administering radiation to the subject in whom the at least one cannabinoid receptor agonist is present so as to treat the condition.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: October 24, 2023
    Assignee: THERALASE TECHNOLOGIES, INC.
    Inventors: Roger Dumoulin-White, Arkady Mandel
  • Patent number: 11464798
    Abstract: A method for treating a tumor in a patient by administering to the patient an immunogenic composition including antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation, wherein the immunogenic composition is effective to elicit an immune response to the antigenic material in the patient after administration and the metal-based coordination complex having a specified formula. An immunogenic composition and a method for preparing it are also disclosed.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: October 11, 2022
    Assignee: THERALASE TECHNOLOGIES INC.
    Inventor: Arkady Mandel
  • Patent number: 11241587
    Abstract: Apparatus for illuminating comprises one or more fibers, the one or more fibers including fiber portions meeting at an apex and a bottom location to form a three dimensional cage; a detector attached to each of the fiber portions for receiving light and transmitting light along each of the fiber portions, respectively; and an illumination member situated within the cage. A method for illuminating a hollow member includes the steps of inserting one or more fibers into the hollow member, wherein one or more fibers include fiber portions that meet at a location to form a three-dimensional cage; permitting light to emit from within the three-dimensional cage and towards the fiber portions; receiving light at distinct locations on each of said fibers; and allowing each of the fibers to transmit the light received on each of the fiber portions out of the hollow member.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: February 8, 2022
    Assignees: Theralase Technologies, Inc., University Health Network
    Inventors: Lothar Lilge, Arkady Mandel, Wayne Embree, Don Lem, Jenny Wu, Roger Dumoulin-White
  • Patent number: 10525279
    Abstract: A method for treating a condition in a tissue, includes the steps: (1) providing a PS within the tissue; (2) irradiating the tissue containing the PS with a first light of a first wavelength; and (3) irradiating the tissue containing the PS with a second light of a second wavelength so as to treat the condition in the tissue, wherein: (a) the PS absorbs light at the first wavelength and the second wavelength; and (b) the second light is more strongly absorbed by the tissue than the first light or vice versa, so as to achieve a predetermined absorbed photon density gradient. An apparatus for conducting the method includes first and second light sources, a power supply, a focusing device, and a controller which adjusts light emission such that I(d)=I(?1 at d=0)×exp (?eff (?1)×d)+I(?2 at d=0)×exp (?eff(?2)?d).
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 7, 2020
    Assignee: Theralase Technologies, Inc.
    Inventors: Arkady Mandel, Roger Dumoulin-White, Wayne Embree
  • Patent number: 10335608
    Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a photodynamic compound containing at least one transition metal; and (b) irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation includes ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The ionizing radiation is preferably X-rays and/or gamma rays. The non-ionizing radiation is preferably light in the range from 600-950 nm.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: July 2, 2019
    Assignees: THERALASE TECHNOLOGIES, INC., UNIVERSITY HEALTH NETWORK
    Inventors: Arkady Mandel, Carl Fisher, Lothar Lilge
  • Patent number: 10111936
    Abstract: Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable photodynamic compounds. The compositions are useful as in vivo diagnostic agents, and as therapeutic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer. Compositions of the invention are further capable of destroying microbial cells, such as bacteria, fungi, and protozoa, and destroying viruses. Treatment methods of the invention can treat conditions throughout the body, including conditions located across the blood-brain barrier, the retina-blood barrier and the blood-cerebrospinal fluid barrier.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: October 30, 2018
    Assignee: Theralase Technologies, Inc.
    Inventor: Arkady Mandel
  • Patent number: 9737565
    Abstract: Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable photodynamic compounds. The compositions are useful as in vivo diagnostic agents, and as therapeutic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer. Compositions of the invention are further capable of destroying microbial cells, such as bacteria, fungi, and protozoa, and destroying viruses.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: August 22, 2017
    Assignee: THERALASE TECHNOLOGIES, INC.
    Inventor: Arkady Mandel